Instrument Inactif

Communiqués Pear Therapeutics, Inc.

Actions

PEAR

US7047231052

Recherche biotechnologique et médicale

Communiqués

10/04/23	PEAR THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
10/04/23	PEAR THERAPEUTICS FILES FOR CHAPTER 11 AND WILL SEEK TO SELL ASSETS THROUGH SALES PROCESS	AQ
07/04/23	PEAR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
07/04/23	Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process	BU
31/03/23	PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
20/03/23	PEAR THERAPEUTICS ANNOUNCES PROCESS EXPLORING STRATEGIC ALTERNATIVES	AQ
17/03/23	PEAR THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
17/03/23	Pear Therapeutics Announces Process Exploring Strategic Alternatives	BU
27/02/23	Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference	BU
24/02/23	PEAR THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events (form 8-K)	AQ
02/02/23	Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference	BU
26/01/23	Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders	BU
19/01/23	PEAR THERAPEUTICS ANNOUNCES INCLUSION OF RESET AND RESET-O ON THE JANUARY 2023 FLORIDA MEDICAID PREFERRED DRUG LIST	AQ
18/01/23	Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat Series	AQ
18/01/23	Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List	BU
17/01/23	Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series	BU
12/01/23	California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program	BU
10/01/23	Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics	BU
04/01/23	Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States	BU
03/01/23	PEAR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
16/12/22	PEAR THERAPEUTICS PRESENTS REAL-WORLD CLINICAL DATA ASSESSING ENGAGEMENT AND ABSTINENCE IN PATIENTS WITH ALCOHOL USE DISORDERS USING RESETAT AAAP	AQ
15/12/22	Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP	BU
21/11/22	Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference	BU
14/11/22	PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
14/11/22	PEAR THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits (form 8-K)	AQ